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ABSTRACT The osteoclast variant of the vacuolar H1-ATPase (V-ATPase) is a potential therapeutic target for combating the
excessive bone resorption that is involved in osteoporosis. The most potent in a series of synthetic inhibitors based on 5-(5,6-
dichloro-2-indolyl)-2-methoxy-2,4-pentadienamide (INDOL0) has demonstrated speciﬁcity for the osteoclast enzyme, over other
V-ATPases. Interaction of two nitroxide spin-labeled derivatives (INDOL6and INDOL5)with theV-ATPase is studied here by using
the transport-active 16-kDa proteolipid analog of subunit c from the hepatopancreas of Nephrops norvegicus, in conjunction with
electron paramagnetic resonance (EPR) spectroscopy. Analogous experiments are also performed with vacuolar membranes
from Saccharomyces cerevisiae, in which subunit c of the V-ATPase is replaced functionally by theNephrops 16-kDa proteolipid.
The INDOL5 derivative is designed to optimize detection of interaction with theV-ATPase byEPR. Inmembranous preparations of
the Nephrops 16-kDa proteolipid, the EPR spectra of INDOL5 contain a motionally restricted component that arises from direct
association of the indolyl inhibitor with the transmembrane domain of the proteolipid subunit c. A similar, but considerably smaller,
motionally restricted population is detected in the EPR spectra of the INDOL6 derivative in vacuolar membranes, in addition to the
larger population from INDOL6 in the ﬂuid bilayer regions of themembrane. Thepotent classical V-ATPase inhibitor concanamycin
A at high concentrations induces motional restriction of INDOL5, which masks the spectral effects of displacement at lower
concentrations of concanamycin A. The INDOL6 derivative, which is closest to the parent INDOL0 inhibitor, displays limited
subtype speciﬁcity for the osteoclast V-ATPase, with an IC50 in the 10-nanomolar range.
INTRODUCTION
Vacuolar H1-ATPases are proton pumps that are responsible
for the acidiﬁcation of intracellular organelles (1). In the os-
teoclast variant, the vacuolar H1-ATPase (V-ATPase) is lo-
cated in a specialized region of the plasma membrane and
induces acidiﬁcation of the extracellular lacunae at the surface
of the resorbing bone (2). Pathology in this remodeling of the
bone leads to osteoporosis. Based on structure-function rela-
tionships for the macrolide antibiotics concanamycin and
baﬁlomycin, which are speciﬁc inhibitors of the V-ATPases,
Farina and colleagues have designed a series of synthetic inhib-
itors comprising the 5-(5,6-dichloro-2-indolyl)-2-methoxy-
2,4-pentadienamide family (3–5). One of the most potent
discovered so far is the 1,2,2,6,6-pentamethyl-piperidin-4-yl
derivative, INDOL0 (see Fig. 1), which exhibits a selectivity
for the osteoclast enzyme over other V-ATPases (6) and is
found to be efﬁcient in preventing bone loss in animal models
of osteoporosis (7). Recently, we have synthesized two spin-
labeled derivatives of this lead therapeutic compound (see
Fig. 1) and characterized the interactionswith lipidmembranes
by using electron paramagnetic resonance (EPR) spectros-
copy (8,9). One derivative, INDOL6, is the nitroxide variant of
the parent compound, INDOL0. The other derivative, INDOL5,
is a spin-labeled analog that was designed to have EPR spec-
tral properties optimized for the detection of interaction with
the membrane-bound V-ATPase.
Spin-label EPR has been used widely to study the interac-
tions of membrane-embedded proteins with the surround-
ing lipid-milieu (see, e.g., 10–13). Both stoichiometry and
selectivity of lipid-protein interactions, and under favorable
circumstances also lipid exchange rates, may be determined
(14–18). Spin-labeled lipids have additionally been used to
investigate the binding site for aminated local anesthetics as
noncompetitive blockers of the nicotinic acetylcholine
receptor (19). More direct information on interaction with
the receptor has been obtained, however, by use of spin-
labeled derivatives of the local anesthetics themselves (20).
For all the above studies, it is necessary that the spin-labeled
species interacting with the protein be resolved spectrally
from that in the bulk lipid environment by virtue of its re-
duced rotational mobility. This can be achieved by varying
the length of attachment of the spin-labeled group, as in
INDOL5 and INDOL6 in Fig. 1. Guiding design principles
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are offered by studies of lipid-protein interactions with spin
labels located at different positions in the lipid chain (21–
23). The ability to resolve the spectral components is de-
termined by the ﬂexibility of the spin-label attachment in the
ﬂuid lipid environment, and not by the thermodynamic af-
ﬁnity of the spin-labeled species for the protein. Both the
latter and the stoichiometry of interaction determine the rela-
tive proportions of the two components, which are quantitated
by difference spectroscopy (24).
In this work, we investigate the interaction of the spin-
labeled indolyl inhibitors with the V-ATPase in yeast vacu-
olar membranes, and in membranes from the hepatopancreas
of Nephrops norvegicus that contain almost exclusively the
16-kDa proteolipid analog of the V-ATPase c-subunit. In the
yeast vacuolar membranes, the native c-subunit that is en-
coded by the VMA3 gene is replaced by recombinant 16-kDa
Nephrops proteolipid to produce a transport-competent
V-ATPase (25,26). Direct interactions of the spin-labeled
inhibitors with the transmembrane Vo-sector of the enzyme
are detected by EPR spectroscopy, in a manner similar to that
used previously to study the association of spin-labeled local
anesthetics with the nicotinic acetylcholine receptor (20).
These studies are augmented by investigation of the effects of
the classical V-ATPase inhibitor concanamycin A on the
interaction with the inhibitor spin labels. This EPR investiga-
tion with spin-labeled inhibitors complements that conducted
previously on the interaction of the unlabeled V-ATPase
inhibitors, concanamycin A and INDOL0, as registered by
EPR spectroscopy of the site-speciﬁcally spin-labeled protein
(27). In addition, we have characterized the subtype selectiv-
ity of V-ATPase inhibition by the spin-labeled (2-indolyl)-
pentadienes, by using microsomes derived from chicken
medullary bone and from chicken brain, in addition to yeast
vacuoles.
MATERIALS AND METHODS
Materials
Concanamycin A was obtained from Fluka (Buchs, Switzerland). Dimyristoyl
phosphatidylcholine was from Avanti Polar Lipids (Alabaster, AL). The
inhibitor INDOL0 (also known as SB 242754) was synthesized according to
the literature (3,6). Spin-labeled 5-(5,6-dichloro-2-indolyl)-2,4-pentadienoyl
inhibitors INDOL6 and INDOL5 (see Fig. 1) were synthesized as described
in Dixon et al. (9). The Saccharomyces cerevisiae W303-1B vatc cells
(MATa ade2, ura3, leu2 his3, trp1, Dvma3TLEU2) were a kind gift of
Nathan Nelson, University of Tel-Aviv (25).
Isolation of 16-kDa membranes and
vacuolar membranes
Endogenous membranes containing the 16-kDa channel proteolipid were
prepared from the hepatopancreas of the decapod Nephrops norvegicus by
extraction with n-lauryl sarcosine, or with 20 mM NaOH, according to the
procedures in the literature ((28–30) and (31,32), respectively). These
membranous preparations contain the endogenous lipids, but the amount of
lipid is strongly reduced in the preparations extracted with N-lauroyl sarcosine
(33). EDTA-washed yeast vacuolar membranes transfected with Nephrops
16-kDa proteolipid were prepared as described in Uchida et al. (34). Pro-
teolipid refers here to the classical deﬁnition of a hydrophobic protein; it
does not imply lipoylation.
Spin-labeling
Membranes, either Nephrops 16-kDa membranes or yeast vacuolar mem-
branes, were suspended in 50 mM borate buffer with 10 mM NaCl, pH 9.0,
or in 50 mMHEPES buffer with 10 mMNaCl and 10 mM EDTA, at pH 7.8,
respectively. Spin-labeled inhibitors were added to membranes (;1 mg mem-
brane protein) in 500 ml of buffer from concentrated solutions in ,10 ml
dimethyl sulfoxide (DMSO). Nominal spin-labeled inhibitor to protein mole
ratio was 1:1 or less (for 16-kDa membranes). When required, concanamycin
A was added similarly in concentrated DMSO solution. After incubation for
30 min, membranes were packed in 1-mm i.d. glass capillaries by pelleting
in a benchtop centrifuge. Sample length was trimmed to 5 mm, excess su-
pernatant was removed, and the capillary was ﬂame-sealed.
EPR spectroscopy
EPR spectra were recorded on a Bruker EMX9-GHz spectrometer (Rheinstetten,
Germany). Sample capillaries were accommodated in standard quartz EPR
tubes that contained light silicone oil for thermal stability. Temperature was
regulated by thermostated nitrogen gas-ﬂow, and measured with a ﬁne-wire
FIGURE 1 Chemical structures of 5-(2-indolyl)-2,4-pentadienoyl deriv-
atives. INDOL0 is the parent inhibitor compound, and INDOL6 and
INDOL5 are spin-labeled derivatives.
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thermocouple situated in the silicone oil at the top of the microwave cavity.
Analysis of two-component EPR spectra was performed as described in Pa´li
et al. (33), using a spectral library obtained from spin-labeled small
unilamellar vesicles of dimyristoyl phosphatidylcholine (35). In spectral
addition, the whole of the two-component experimental spectrum was ﬁtted
ﬁrst, and then the relative weights of the two components were optimized on
the low-ﬁeld hyperﬁne lines. Note that choosing the best-matching ﬂuid
component from a spectral library corrects not only for perturbations of the
bulk lipid mobility by the presence of the protein, but also largely corrects
for any lifetime broadening that arises from exchange on and off the protein
(see, e.g., (36)). Comparison of the results of spectral subtraction with
spectral simulations for two-site exchange shows that this subtraction pro-
tocol largely corrects for the effects of exchange and yields reliable values
for the relative proportions of the two spectral components (12,17,37). If, at
the same lipid/protein ratio, f1 and f2 are the fractions of two motionally
restricted spin-labeled species that compete for the same sites on the protein,
then the ratio of their average association constants (K1/K2) is given by
K1/K2 ¼ (1/f2–1)/(1/f1–1) (24).
Measurement of V-ATPase activity in yeast
V-ATPase was puriﬁed from yeast vacuolar membranes solubilized in
dodecyl maltoside on discontinuous glycerol gradients, essentially according
to Uchida et al. (34). ATPase activity was assayed at 30C by colorimetric
development of phosphate release using ammonium molybdate, as described in
Harrison et al. (26).
Measurement of V-ATPase H1-transport in
bone-derived microsomes
Chickenmedullary bone-derivedmicrosomes from regularly egg-laying hens
were prepared as described in Va¨a¨na¨nen et al. (38), and the ﬂuorescence-
quench method with acridine orange was used to monitor microsome acid-
iﬁcation. Themicrosomes were diluted in a buffer containing 150mMKCl, 5
mMMgSO4, 1.5mMacridine orange, 1mMvalinomycin, and 5mMHEPES/
Tris, pH 7.4, and aliquoted in a 96-well plate. Inhibitors were added inDMSO
(1% ﬁnal concentration) and incubated for 20–40 min before ﬂuorescence
measurement in a microtiter plate reader (Cameleon, Hidex, Finland). Acid-
iﬁcationwas initiated by addition ofATP to a ﬁnal concentration of 5mM. Six
wellswere treated simultaneously: control and ﬁve different concentrations of
inhibitor. Readings of acridine orange ﬂuorescence (480 nm excitation, 535
nm emission) were taken every 30 s. At the end of the assay, nigericin was
added (10 mg/ml ﬁnal concentration) to conﬁrm that a transmembrane proton
gradient had been established. For calculation of the percentage inhibition, the
initial linear slope of the ﬂuorescence-time curve was used to determine the
rate of acidiﬁcation. For comparison, assays were also performed with brain
microsomes derived from chicken cerebrum and cerebellum. These were
prepared by methods similar to those for the osteoclast microsomes.
Sequence alignments
Amino-acid sequences were taken from the PIR Database. Sequence
alignments were performed with CLUSTAL W (39) and displayed with the
PIR alignment viewer.
RESULTS AND DISCUSSION
Experiments with spin-labeled inhibitors were performed using
membranous preparations of the 16-kDa proteolipid subunit
from Nephrops norvegicus, which contain almost exclu-
sively the analog of vacuolar subunit c, at high concentration.
Corresponding experiments were also performed on yeast
vacuolar membranes in which the endogenous subunit c of the
V-ATPase was replaced by the Nephrops 16-kDa proteolipid.
Inhibition studies were carried out both with puriﬁed yeast
vacuolar membranes, and with microsomes prepared from
chicken medullary bone and from chicken brain tissue.
The strong degree of homology between V-ATPase subunits-c
from different species ensures the relevance of these experi-
mental systems. This is illustrated by the fact that the 16-kDa
proteolipid from Nephrops substitutes for subunit c in yeast
(25,26). As seen from the alignments in Fig. 2, the yeast
V-ATPase subunit c has 69% identity with the Nephrops
protein, and the human subunit c has 80% identity with
Nephrops. Also, a putative protein from chicken has 81%
identity with Nephrops 16-kDa proteolipid.
Nephrops 16-kDa proteolipid membranes
Fig. 3 shows the temperature dependence of the EPR spectra
from 16-kDa proteolipid membranes to which the spin-labeled
inhibitor INDOL5 has been added. At intermediate and higher
temperatures, the EPR spectra clearly consist of two com-
ponents. The relatively sharp, three-line spectral component,
the outer lines of which are indicated by dashed arrows, is
assigned to the mobile population of INDOL5 spin-labels in
ﬂuid bilayer regions of the membrane. This assignment is
FIGURE 2 Alignment of the amino-acid se-
quences for the 16-kDa proteolipid, V-ATPase
subunit c from different species. Data are taken
from the PIR database with the following
Uniprot KB accession codes: human, P27449;
chicken, Q5ZJ19; Nephrops, Q26250; yeast,
P25515.
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made by comparison with the single EPR spectral compo-
nent that is observed in ﬂuid bilayer membranes composed
of phospholipid alone (9). The broad component that is re-
solved in the outer wings of the spectrum, and is indicated by
the solid arrows in Fig. 3, is therefore assigned to the pop-
ulation of spin-labeled INDOL5 inhibitors that are restricted
in their motion by interacting directly with the protein. Be-
cause the 16-kDa proteolipid does not project appreciably
from the membrane surface (25,33), the INDOL5 spin label
must be associated, therefore, with the transmembrane sec-
tion of the 16-kDa subunit c.
The spin-labeled indole derivative INDOL5 was designed
speciﬁcally to optimize resolution of the two-component EPR
spectra in Nephrops membranes, which contain a high con-
centration of cholesterol and have a high protein density (see
(9)). Resolution of the two spectral components is achieved at
temperatures of 37C and higher. At lower temperatures, the
mobility of the lipid chains in the bilayer regions of the mem-
brane is reduced considerably, and the spectrum of INDOL5
in these regions then strongly overlaps that of INDOL5 as-
sociated directly with the protein. EPR spectra of the latter
are not as strongly temperature-dependent because they lie in
the slow-motion regime of nitroxide EPR spectroscopy. At
6C, they resemble an anisotropic powder pattern, with small,
sharp lines superimposed that arise from a small amount of
free, aqueous spin label. Note that the 16-kDa proteolipid is
an extremely heat-stable protein (25).
The fraction of INDOL5 spin label that gives rise to the
broad, motionally restricted component in the spectra of Fig.
3, at 43C and above, was determined by comparison with
library spectra that best matched each of the two compo-
nents. Linear combinations of the single-component spectra
(see inset to Fig. 3) were ﬁtted to the two-component experi-
mental spectra. Approximately 666 3% of the INDOL5 spin
label is motionally restricted by direct interaction with the
16 kDa protein (mean over 43–61C). For comparison, it was
found previously that 60–70% of spin-labeled phosphatidyl-
choline was motionally restricted in similar 16-kDa proteo-
lipid membranes from Nephrops (33). Thus, the spin-labeled
indole inhibitor either samples the whole of the hydrophobic
surface of the 16-kDa protein that is available to lipid in these
closely packed membranes, or it is restricted to a more lim-
ited number of sites at the lipid-protein interface, for which it
exhibits a higher speciﬁcity. Experiments at probe concentra-
tions are unable to distinguish between these two possibilities
(see, e.g., (36,40)). For alkali-extracted 16-kDa membranes
from Nephrops, in which the protein is less densely packed,
;60% of spin-labeled INDOL5 is motionally restricted,
whereas only ;30% of spin-labeled phosphatidylcholine is
motionally restricted in such membranes (33). This implies a
selectivity for the spin-labeled indole that is characterized by
an approximately fourfold greater average association con-
stant compared with phosphatidylcholine (see Materials and
Methods and (24)). It should be remembered that modest
values of the relative association constants in membrane sys-
tems can achieve the same degree of occupancy as much larger
binding constants (in mole fraction units) in solution, be-
cause of the reduction in dimensionality in membranes (41).
Note that, at the highest temperatures of measurement, the
linewidths of the component from spin labels in the ﬂuid
lipid environment are still relatively broad. The peak-to-peak
linewidth of the diagnostic low-ﬁeld line is DH
ðfÞ
pp;4G:
This considerably exceeds the line-broadening that might be
produced by exchange effects. The intrinsic exchange rates
FIGURE 3 EPR spectra of spin-labeled in-
dole, INDOL5, in 16-kDa proteolipid mem-
branes fromNephrops norvegicus. Spectra were
recorded at the temperatures indicated in the
ﬁgure. The spectral component from the mo-
tionally restricted population of INDOL5 is
indicated by solid arrows; that from the mobile
(ﬂuid-bilayer) component is indicated by dashed
arrows. The small, sharp component that ap-
pears close to the position of the dashed arrows
in the spectrum at 6C arises from free, aqueous
spin label. Total scanwidth¼ 150G. (Inset) The
single-component spectra at 43C.
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of spin-labeled phospholipids that display no selectivity of
lipid-protein interaction are in the range t1b ;10
7s1 for
various membrane proteins (24). This is almost an order-of-
magnitude slower than diffusional lipid exchange in ﬂuid bi-
layers: t1diff;10
8s1 (42,43). For comparable populations of
free and protein-associated spin labels (i.e., t1f ;t
1
b ), the con-
tribution of molecular exchange to the low-ﬁeld linewidth
of the free component is therefore maximally dDH
ðfÞ
pp ¼
ð2= ﬃﬃﬃ3p Þðh=gbÞt1f ;0:7G (see (36)). Additionally, as noted
already in Materials and Methods, the ﬁtting strategy of
choosing the best ﬁtting ﬂuid component from a library of
phosphatidylcholine-vesicle spectra largely corrects for con-
tributions to the linewidth from exchange. The result is that
relative populations of the spin-label species are estimated
reliably by this strategy.
Yeast vacuolar membranes
Fig. 4 shows the temperature dependence of the EPR spectra
from yeast vacuolar membranes to which the spin-labeled
inhibitor INDOL6 has been added. At low temperatures, the
spectral extent or anisotropy is less than that of INDOL5,
even though the latter spin-labeled derivative possesses
greater intrinsic segmental mobility (9). Table 1 gives values
of the outer hyperﬁne splitting, 2Amax, of both INDOL6 and
INDOL5 derivatives in Nephrops membranes and vacuolar
membranes, and in lipid bilayer membranes of dimyristoyl
phosphatidylcholine. From this, the higher rotational mobil-
ity of INDOL5, which gives rise to a greater motional aver-
aging of the outer hyperﬁne splitting than that of INDOL6, is
evident in both Nephrops membranes and dimyristoyl phos-
phatidylcholine bilayers. The smaller values of 2Amax for
INDOL6 in yeast vacuolar membranes, relative to those in
Nephrops membranes, reﬂect the higher lipid mobility and
the lower intramembranous protein density in the vacuolar
membranes.
Although the resolution is not as good as in Fig. 3, a small
motionally restricted component is present in the outer wings
of the EPR spectra of INDOL6 in vacuolar membranes. The
position of this component is indicated by the dotted lines in
Fig. 4 (see also inset). It is evident as an asymmetry of the
high-ﬁeld peak at lower temperatures, and as a shoulder on
the low-ﬁeld peak at intermediate temperatures. As inNephrops
membranes, this motionally restricted component is attrib-
uted to a population of INDOL6 that is interacting directly
with the membrane protein. The intensity is lower than that
of the motionally restricted component in Fig. 3, because of
the lower intramembranous protein density in the vacuolar
membranes. In view of the highly hydrophobic nature of
INDOL6, as evidenced by the interaction with lipid mem-
branes (9), and by analogy with the motional restriction of
spin-labeled lipids in Nephrops membranes (33) and spin-
labeled local anesthetics in Torpedo membranes (20), this
motionally restricted population of INDOL6 is also associ-
ated with the transmembrane protein domains in vacuolar
membranes, particularly those of the V-ATPase.
FIGURE 4 EPR spectra of spin-labeled in-
dole, INDOL6, in yeast vacuolar membranes.
Spectra were recorded at the temperatures
indicated in the ﬁgure. The spectral component
from the motionally restricted population of
INDOL6 is indicated by the vertical dotted
lines. Total scan width ¼ 150 G. (Inset) The
single-component ﬂuid spectrum at 60C.
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Spin-labeled inhibitors in the presence of
concanamycin A
Fig. 5 shows the EPR spectra of INDOL5 in Nephrops 16-
kDa proteolipid membranes in the presence of concanamycin
A, at various temperatures. The amounts of concanamycin A
added were: 0:1, 1:1, and 5:1 mol/mol, relative to INDOL5.
Adding an equimolar amount of concanamycin A, relative to
spin-labeled inhibitor, produces little difference in the rela-
tive population of motionally restricted INDOL5 (see dotted
lines in Fig. 5). However, adding an excess of concanamycin
A produces a pronounced increase in the population of mo-
tionally restricted INDOL5 (dashed lines in Fig. 5). The lat-
ter is an effect that is shared also with spin-labeled lipids, the
motionally restricted population of which is increased on add-
ing concanamycin A to 16-kDa membranes (data not shown).
This general feature of the interactions of concanamycin A
with these membranes tends to mask any displacement of the
indole inhibitor by concanamycin.
Quantiﬁcation of the spectra shown in Fig. 5, and others at
intermediate temperatures, was performed by ﬁtting a linear
combination of library spectral components to each two-
component spectrum. In the absence of concanamycin A, the
fraction of motionally restricted INDOL5 spin label is f ¼
0.66 6 0.03, and that in the presence of equimolar concana-
mycin A is f ¼ 0.64 6 0.03. Increasing the concanamycin A
concentration ﬁvefold, however, increases the fraction of
motionally restricted INDOL5 to f ¼ 0.78 6 0.03. That
INDOL5 should be displaced from the inhibitory site by
concanamycin A can be inferred from studies of their relative
potencies that are given later. This suggests that displace-
ment of INDOL5 is compensated in the EPR spectrum by the
additional immobilizing potential of concanamycin A that
comes to dominate at higher concentrations. Varying the con-
centration of concanamycin A in the lower range has failed
to reveal a window where the displacement dominates. Pre-
vious data on the site-speciﬁcally labeled protein suggest that
the indole inhibitors compete with concanamycin A for simi-
lar sites on the transmembrane domain of the 16-kDa proteo-
lipid subunit c (27).
Fig. 6 shows the EPR spectra of INDOL6 in yeast vacuolar
membranes in the presence of concanamycin A, at various
temperatures. The amount of concanamycin A added was 0:1
and 2:1 mol/mol, relative to INDOL6. The effect of concana-
mycin A in increasing the population of motionally restricted
species is also evident here, for INDOL6 in yeast vacuolar
membranes. Competition would not be observed in this ex-
periment, because of the low intrinsic population ofmotionally
restricted INDOL6 in vacuolar membranes (see above).
Inhibition assays
To compare the inhibitory potency of the spin-labeled indole
compounds with that of the parent INDOL0, we prepared
TABLE 1 Temperature dependence of the outer hyperﬁne
splitting, 2Amax (Gauss), in the EPR spectra of the INDOL6
and INDOL5 spin-labeled V-ATPase inhibitors in Nephrops
16-kDa proteolipid membranes, and yeast vacuolar membranes,
and in dimyristoyl phosphatidylcholine bilayer membranes
Inhibitor 6C 24C 40C
Nephrops 16-kDa
INDOL6 67.9 65.7 64.0
INDOL5 65.6 64.5 62.5,* 37y
Yeast vacuolar
INDOL6 59.8 52.2 45.1
Dimyristoyl
phosphatidylcholine
INDOL6 60.1 53.5 47.1
INDOL5 58.2 45.7 34.5
*Motionally restricted component.
yFluid component.
FIGURE 5 EPR spectra of spin-labeled in-
dole, INDOL5 (150 mM), in Nephrops 16-kDa
proteolipid membranes to which concanamycin
A was added. (Solid line) No concanamycin A;
(dotted line) 150 mM concanamycin A; (dashed
line) 750 mM concanamycin A. Spectra were
recorded at the temperatures indicated in the
ﬁgure. Total scan width ¼ 150 G.
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microsomes from medullary bone of regularly egg-laying
hens, which is a source rich in osteoclasts. For additional
comparison, we also used microsomes prepared from chicken
brain tissue. Acidiﬁcation of the microsomes was detected as
the quenching of ﬂuorescence from entrapped acridine orange.
The ﬂuorescence quenching was fully inhibited by 30 nM
baﬁlomycin, conﬁrming that the H1-uptake observed was
mediated by the V-ATPase. Fig. 7 shows the inhibition curves
for the three indole compounds, and for baﬁlomycin A1, that
are obtained with chicken medullary bone microsomes (upper
panel), and with chicken brain microsomes (lower panel). In-
dole concentrations required for 50% inhibition are listed in
Table 2. The IC50 values for the parent compound, INDOL0,
are;20 nM and 100 nM for acidiﬁcation of bone-and brain-
derived microsomes, respectively. This pronounced selec-
tivity for the osteoclast enzyme is in agreement with previous
observations by Nadler et al. (6), who analyzed selectivity by
using microsomes from chicken medullary bone and chicken
adrenal glands.
The spin-labeled derivative INDOL6 is at least as potent
as the parent compound in bone microsomes (IC50 15 nM),
and apparently more potent than INDOL0 in brain micro-
somes (IC50 20 nM). Correspondingly, however, INDOL6
displays a reduced selectivity for the osteoclast enzyme rela-
tive to the brain enzyme, as compared with that of INDOL0
(see Table 2). The other spin-labeled derivative, INDOL5, is
far less potent an inhibitor than is INDOL6, with an IC50 of
;5 mM for both bone-derived and brain-derived micro-
somes. This latter spin-labeled derivative was chosen for its
spectroscopic properties in Nephrops 16-kDa proteolipid mem-
branes, which contain only subunit c, at high concentration.
Inhibition of V-ATPase activity was also assayed using pu-
riﬁed vacuolar membranes from Saccharomyces cerevisiae in
which the endogenous subunit c was replaced by the Nephrops
16-kD proteolipid. Fig. 8 shows inhibition curves for the
indole inhibitors, and for concanamycin A. The inhibitory
potencies of the indole derivatives differ from those for the
osteoclast enzyme. The IC50 for INDOL0 is ;13 nM and
FIGURE 6 EPR spectra of spin-labeled indole,
INDOL6 (25 mM), in yeast vacuolar membranes
to which concanamycin Awas added. (Solid line)
No concanamycin A; (dashed line) 50 mM
concanamycin A. Spectra were recorded at the
temperatures indicated in the ﬁgure. Total scan
width ¼ 150 G.
FIGURE 7 Inhibitor proﬁle of V-ATPase H1-transport activity in chicken
medullary bone microsomes (upper panel) and chicken brain microsomes
(lower panel). Activity in the presence of inhibitors is shown as percentage
of the initial rate of internal acidiﬁcation, relative to that in the absence of
inhibitors. (Open squares) INDOL0; (solid squares) INDOL6; (circles)
INDOL5; and (diamonds) baﬁlomycin A1.
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that for INDOL6 is 4 6 1 mM, i.e., the spin-labeled de-
rivative is far less potent in yeast than is the parent com-
pound. No inhibition was found for INDOL5 at 100 mM;
therefore the IC50 for this indole must lie at least in the mil-
limolar range, when assayed with yeast vacuolar membranes
(data not shown). This reduction in potency for INDOL5 is at
least comparable to that in the bone-derived microsomes.
Note that the 5000-fold lower IC50 of concanamycin relative
to INDOL5 should ensure displacement of the latter by equi-
molar concanamycin. This supports our interpretation of the
EPR data: that the displacement is masked by the additional
immobilizing potential of concanamycin.
The spin-label derivatives INDOL6 and INDOL5 exhibit a
pronounced subtype speciﬁcity for inhibition of the osteoclast
V-ATPase over that of the yeast enzyme. Also, INDOL6 does
not exhibit any reduction in potency relative to the parent
INDOL0 for inhibition of the osteoclast V-ATPase, unlike
the situation with the yeast enzyme. (Note that the human
V-ATPase subunit c bears 80% identity to the Nephrops
16-kDa proteolipid, as does the putative protein identiﬁed
from chicken; see Fig. 2.) Bioavailability, however, may
play a signiﬁcant role in any inter-species comparison. This
is illustrated, for instance, by the fact that INDOL0 inhibits
yeast V-ATPase puriﬁed on glycerol gradients (IC50 3.56
1 nM; (44)) more potently than it does in vacuolar membrane
preparations (IC50  13 nM).
CONCLUSIONS
The spin-labeled indolyl inhibitors allow direct demonstra-
tion of the association of this class of compounds with the
transmembrane domain of the V-ATPase proteolipid subunit
c. This is achieved by means of a speciﬁc, motionally broad-
ened, anisotropic component that is resolved in their EPR
spectrum. Attempts to demonstrate displacement of INDOL5
by concanamycin A were unsuccessful because of the in-
trinsic immobilizing effect of concanamycin. Our previous
results with spin-labeled 16-kDa proteolipid suggest that the
sites for both inhibitors are close to the glutamic acid residue
E140 that is essential for proton translocation (27). The spec-
iﬁcity found for the osteoclast V-ATPase, relative to yeast,
indicates that the spin-labeled INDOL6 inhibitor could be
used to explore the basis for functional selectivities. This sub-
type selectivity extends also to the INDOL5 spin-label deriv-
ative (but not relative to chicken brain, in the latter case).
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